+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Spinal Muscular Atrophy - Global Strategic Business Report

  • PDF Icon

    Report

  • 189 Pages
  • May 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309879
The global market for Spinal Muscular Atrophy is estimated at US$1.6 Billion in 2023 and is projected to reach US$3.5 Billion by 2030, growing at a CAGR of 12.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Type 1 Spinal Muscular Atrophy segment, which is expected to reach US$2.1 Billion by 2030 with a CAGR of a 12.8%. The Type 2 Spinal Muscular Atrophy segment is also set to grow at 11.7% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $480.9 Million in 2023, and China, forecasted to grow at an impressive 11.5% CAGR to reach $604.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Spinal Muscular Atrophy Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Spinal Muscular Atrophy Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Spinal Muscular Atrophy Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AveXis, Inc., Biogen Inc., Cytokinetics, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 31 Featured):

  • AveXis, Inc.
  • Biogen Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Spinal Muscular Atrophy - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Type 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Type 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Type 1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Type 2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Type 3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Type 3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Type 3 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Type 4 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Type 4 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Type 4 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 16: World Spinal Muscular Atrophy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 18: USA Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 19: USA 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 21: Canada Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 22: Canada 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
JAPAN
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 23: Japan Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 24: Japan Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 25: Japan 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
CHINA
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 26: China Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 27: China Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 28: China 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
EUROPE
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 29: Europe Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Spinal Muscular Atrophy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 31: Europe 16-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 32: Europe Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 34: Europe 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
FRANCE
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 35: France Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 36: France Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 37: France 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
GERMANY
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 38: Germany Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 39: Germany Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 40: Germany 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
ITALY
  • Table 41: Italy Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 42: Italy Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 43: Italy 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 44: UK Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 45: UK Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 46: UK 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 47: Rest of Europe Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 48: Rest of Europe Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 49: Rest of Europe 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Spinal Muscular Atrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 50: Asia-Pacific Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 51: Asia-Pacific Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 52: Asia-Pacific 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 53: Rest of World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • Table 54: Rest of World Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • Table 55: Rest of World 16-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AveXis, Inc.
  • Biogen Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

Table Information